Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients With Relapsed or Refractory Lymphomas

NCT03119467 is registered in ClinicalTrials.gov with Rhizen Pharmaceuticals SA as lead sponsor.

NCT NCT03119467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03119467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients With Relapsed or Refractory Lymphomas
Lead sponsor
Rhizen Pharmaceuticals SA
Phase
Phase 1
Overall status
Terminated
Start date
May 11, 2017
Completion date
December 19, 2019
Enrollment
21 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma